Cargando…
Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical trial
BACKGROUND: In stable patients with type 2 diabetes (T2D), insulin treatment is associated with elevated risk for major adverse cardiovascular events (MACE). Patients with acute coronary syndrome (ACS) and T2D are at particularly high risk for recurrent MACE despite evidence-based therapies. It is u...
Autores principales: | Schwartz, Gregory G., Nicholls, Stephen J., Toth, Peter P., Sweeney, Michael, Halliday, Christopher, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Ginsberg, Henry N., Ray, Kausik K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8218391/ https://www.ncbi.nlm.nih.gov/pubmed/34158057 http://dx.doi.org/10.1186/s12933-021-01311-9 |
Ejemplares similares
-
Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study
por: Nicholls, Stephen J., et al.
Publicado: (2021) -
Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial
por: Cummings, Jeffrey, et al.
Publicado: (2021) -
Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease
por: Toth, Peter P., et al.
Publicado: (2022) -
Benefit of Apabetalone on Plasma Proteins in Renal Disease
por: Wasiak, Sylwia, et al.
Publicado: (2017) -
Aimants fer - béton
por: Chapelle, J-P, et al.
Publicado: (1987)